back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2021-07-08 16:43 Tx date 2021-07-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-32,814
-3,646 vol $9.00 each |
0 | |
| Filed 2021-07-08 16:42 Tx date 2021-07-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$1,385
+3,646 vol $0.38 each |
3,646 | |
| Filed 2021-07-08 16:40 Tx date 2021-07-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-1,385.48
-3,646 vol $0.38 each |
81,427 | |
| Filed 2021-07-02 13:18 Tx date 2021-07-01 |
$TRIL
Trillium Therapeutics Inc. |
Mackey, Catherine Jane
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$649,900
+67,000 vol $9.70 each |
67,000 | |
| Filed 2021-06-30 13:15 Tx date 2021-06-30 |
$TRIL
Trillium Therapeutics Inc. |
Mackey, Catherine Jane
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-06-08 17:49 Tx date 2021-06-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-30,152.42
-3,646 vol $8.27 each |
0 | |
| Filed 2021-06-08 17:48 Tx date 2021-06-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$1,385
+3,646 vol $0.38 each |
3,646 | |
| Filed 2021-06-08 17:45 Tx date 2021-06-07 |
$TRIL
Trillium Therapeutics Inc. |
Uger, Robert
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-1,385.48
-3,646 vol $0.38 each |
85,073 | |
| Filed 2021-05-18 10:52 Tx date 2021-05-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
90 - Change in the nature of ownership
|
+133,555 vol |
408,555 | |
| Filed 2021-05-18 10:50 Tx date 2021-05-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-133,555 vol |
1,550,945 | |
| Filed 2021-05-13 18:07 Tx date 2021-05-12 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-219,880.4958
-23,802 vol $9.24 each |
0 | |
| Filed 2021-05-13 18:06 Tx date 2021-05-12 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$9,044
+23,802 vol $0.38 each |
23,802 | |
| Filed 2021-05-13 18:04 Tx date 2021-05-12 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-9,044.76
-23,802 vol $0.38 each |
1,684,500 | |
| Filed 2021-05-13 18:03 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-176,654.2366
-19,198 vol $9.20 each |
0 | |
| Filed 2021-05-13 18:02 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$7,295
+19,198 vol $0.38 each |
19,198 | |
| Filed 2021-05-13 18:00 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-7,295.24
-19,198 vol $0.38 each |
1,708,302 | |
| Filed 2021-05-13 17:59 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-805,148.75
-87,500 vol $9.20 each |
0 | |
| Filed 2021-05-13 17:57 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$47,250
+87,500 vol $0.54 each |
87,500 | |
| Filed 2021-05-13 17:56 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-05-13 17:53 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-47,250
-87,500 vol $0.54 each |
1,727,500 |